Savara Inc (NASDAQ:SVRA) CFO David L. Lowrance sold 5,275 shares of the company’s stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $12.08, for a total value of $63,722.00. Following the completion of the transaction, the chief financial officer now directly owns 23,080 shares in the company, valued at $278,806.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Savara opened at $12.25 on Thursday, according to MarketBeat Ratings. Savara Inc has a twelve month low of $5.07 and a twelve month high of $17.19. The company has a quick ratio of 16.28, a current ratio of 16.28 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $349.84 million, a PE ratio of -6.96 and a beta of 0.05.
Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Wednesday, May 9th. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.01). equities analysts forecast that Savara Inc will post -1.37 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Sectoral Asset Management Inc bought a new position in Savara during the 4th quarter worth $2,374,000. VHCP Management II LLC bought a new position in Savara during the 4th quarter worth $18,691,000. Brown Advisory Inc. bought a new position in Savara during the 4th quarter worth $2,098,000. Consonance Capital Management LP bought a new position in Savara during the 4th quarter worth $40,899,000. Finally, Virtu Financial LLC bought a new position in Savara during the 4th quarter worth $464,000. Institutional investors and hedge funds own 40.98% of the company’s stock.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.